Biotech Funds Underperform the Broader Market

The biotechnology sector often promises groundbreaking innovation and potential for significant returns. However, this week has painted a less rosy picture for the sector, especially when juxtaposed with the broader market's performance.

Biotech & Genomic Theme Loses Momentum

While the S&P 500 was treading water this week, the Biotech & Genomic theme plunged, recording a loss of 3.75%. It underperformed not just the broader market but also the healthcare sector which edged up 0.03%.

Reasons for the Decline

A deeper dive into the reasons behind the downturn reveals that the performance of several key companies significantly influenced the overall sector decline. Crispr Therapeutics AG (CRSP) saw its market value decrease by 5.77% on profit-taking. Despite this trend reversal, CRSP stocks are still up 26.07% year-to-date. The Switzerland-based company, along with its partner Vertex Pharmaceuticals, recently got regulatory approvals for Casgevy. This is a CRISPR/Cas9 gene-edited cell therapy designed to treat patients aged 12 years and older suffering from severe sickle cell disease or transfusion-dependent beta thalassemia.

Twist Bioscience Corp. (TwST) also faced a downturn, with its value dropping by 3.40% over the week. The most pronounced decline came from Recursion Pharmaceuticals Inc. (RXRX). The rare-disease drug developer experienced a 12.65% drop, weighing heavily on the sector.

Against this backdrop, the Global X Genomics & Biotechnology UCITS ETF (GNOG) lost 4.10% over the week, bringing its year-to-date performance to +3.83%.

Group Data:

Funds Specific Data:

Please note this article is for information purposes only and does not in any way constitute investment advice. It is essential that you seek advice from a registered financial professional prior to making any investment decision.